Research Analysts Issue Forecasts for Assertio Q3 Earnings

Assertio Holdings, Inc. (NASDAQ:ASRT - Free Report) - Stock analysts at Sidoti Csr reduced their Q3 2025 EPS estimates for Assertio in a research report issued on Thursday, March 13th. Sidoti Csr analyst J. Sidoti now anticipates that the company will post earnings of $0.00 per share for the quarter, down from their prior estimate of $0.02. The consensus estimate for Assertio's current full-year earnings is ($0.15) per share. Sidoti Csr also issued estimates for Assertio's Q4 2025 earnings at $0.00 EPS.

Other equities analysts also recently issued research reports about the stock. StockNews.com downgraded shares of Assertio from a "buy" rating to a "hold" rating in a research note on Monday. Industrial Alliance Securities set a $1.75 price objective on shares of Assertio in a research note on Friday, March 14th. Finally, HC Wainwright decreased their price objective on shares of Assertio from $4.00 to $3.50 and set a "buy" rating for the company in a research note on Wednesday.

Assertio Stock Up 0.3 %

Shares of ASRT stock traded up $0.00 on Monday, reaching $0.71. 492,365 shares of the stock were exchanged, compared to its average volume of 761,633. The company has a current ratio of 2.01, a quick ratio of 1.57 and a debt-to-equity ratio of 0.30. The business's 50 day moving average price is $0.80 and its 200 day moving average price is $0.96. The company has a market capitalization of $68.19 million, a price-to-earnings ratio of -0.98, a PEG ratio of 3.25 and a beta of 0.81. Assertio has a twelve month low of $0.68 and a twelve month high of $1.80.

Remove Ads

Institutional Investors Weigh In On Assertio

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Two Sigma Investments LP raised its holdings in shares of Assertio by 3.9% in the fourth quarter. Two Sigma Investments LP now owns 910,046 shares of the company's stock valued at $793,000 after buying an additional 34,004 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Assertio by 21.3% in the fourth quarter. Northern Trust Corp now owns 227,217 shares of the company's stock valued at $198,000 after buying an additional 39,906 shares during the last quarter. Stifel Financial Corp purchased a new stake in shares of Assertio in the fourth quarter valued at about $27,000. Marshall Wace LLP purchased a new position in Assertio during the fourth quarter worth about $64,000. Finally, Geode Capital Management LLC raised its holdings in Assertio by 2.0% during the fourth quarter. Geode Capital Management LLC now owns 1,095,911 shares of the company's stock worth $955,000 after purchasing an additional 21,059 shares in the last quarter. 48.96% of the stock is owned by hedge funds and other institutional investors.

Assertio Company Profile

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.